EMA says benefits of Celltrion's COVID-19 antibody drug inconclusive, real-time review on

Celltrion

26/03/2021 11:32

March 26 (Reuters) - Europe's drug regulator said on Friday
it had finished reviewing South Korean drugmaker Celltrion's
 068270.KS  COVID-19 antibody treatment, and found that while it
may lower hospitalisation rates, it could not reach a conclusion
on its benefits.
    However, the treatment, regdanvimab, can be considered for
treating patients at high risk of getting severely ill, the
European Medicines Agency said, adding that a rolling review of
the treatment for European authorisation is still ongoing. 
    

 (Reporting by Pushkala Aripaka in Bengaluru; Editing by
Ramakrishnan M.)
 ((Pushkala.A@thomsonreuters.com; Twitter: @pullthekart; Mobile:
+91 852 751 3793 ;))